" class="no-js "lang="en-US"> Marc Dunoyer - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Marc Dunoyer

Marc Dunoyer

About Marc Dunoyer

Chief Executive Officer of Alexion, AstraZeneca Rare Disease.

Related Story

Clinical Trials

 Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder | Pharmtech Focus

Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder

May 6 2022

Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab-cwvz) achieved a statistically […]